Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rintatolimod + aspirin + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- AIM ImmunoTech
- Modality
- Small Molecules, RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
rintatolimod + aspirin + interferon alfa-2b is a combination immunotherapy regimen developed by Roswell Park Comprehensive Cancer Center for the neoadjuvant treatment of localized prostate cancer. The regimen, often referred to as a chemokine-modulating (CKM) therapy, consists of rintatolimod (a synthetic double-stranded RNA and TLR3 agonist), enteric-coated aspirin (a COX inhibitor), and recombinant interferon alfa-2b. This combination is designed to reprogram the tumor microenvironment by increasing the production of T-cell-attracting chemokines and decreasing immunosuppressive factors. By mimicking a viral infection through TLR3 activation and inhibiting prostaglandin synthesis, the regimen aims to enhance the infiltration of cytotoxic T lymphocytes into the tumor, potentially improving surgical outcomes and reducing the risk of recurrence in patients undergoing radical prostatectomy.
- Brand names
- AmpligenIntron A
- Other names
- Chemokine-modulating regimenCKM regimenrintatolimod + EC aspirin + interferon-alpha 2b
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on rintatolimod + aspirin + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rintatolimod + aspirin + interferon alfa-2b.